Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

598.82 -6.38 (-1.05%)
Streaming Delayed Price Updated: 1:38 PM EDT, Oct 27, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Medpace Hits 17-Month Low After Bookings Miss Leaves Investors Mystified
The company's bookings missed expectations for the fifth consecutive quarter. Investors are questioning its "path forward." 
Via Investor's Business Daily
Thermo Fisher (TMO) Reports Earnings Tomorrow: What To Expect
Life sciences company Thermo Fisher (NYSE:TMO) will be reporting earnings tomorrow before the bell. Here’s what to expect. 
Via StockStory
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Medpace Holdings Reports Q1 Earnings, Shares Move Lower
Medpace Holdings reports first-quarter financial results after the market close on Monday. Here's a look at the key metrics from the quarter. 
Via Benzinga
Medpace (NASDAQ:MEDP) Beats Expectations in Strong Q1 But Stock Drops
Clinical research company Medpace Holdings (NASDAQ:MEDP) announced better-than-expected revenue in Q1 CY2025, with sales up 9.3% year on year to $558.6 million. The company’s full-year revenue guidance... 
Via StockStory
Insights into Medpace Hldgs's Upcoming Earnings
 
Via Benzinga
Medpace Holdings, Inc. Reports First Quarter 2025 Results
From Medpace Holdings, Inc.
Via Business Wire
Earnings Scheduled For April 21, 2025
 
Via Benzinga
Medpace (MEDP) Q1 Earnings: What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
What 5 Analyst Ratings Have To Say About Medpace Hldgs
 
Via Benzinga
1 Spectacular Growth Stock Down 34% to Buy Hand Over Fist
Via The Motley Fool
Topics Initial Public Offering
3 Market-Beating Stocks with Solid Fundamentals
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
1 Healthcare Stock with Solid Fundamentals and 2 to Ignore
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
This Kraft Heinz Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Drug Development Inputs & Services Stocks Q4 In Review: Medpace (NASDAQ:MEDP) Vs Peers
Wrapping up Q4 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Medpace (NASDAQ:MEDP) and its peers. 
Via StockStory
Medpace Holdings, Inc. to Report First Quarter 2025 Financial Results on April 21, 2025
From Medpace Holdings, Inc.
Via Business Wire
Drug Development Inputs & Services Stocks Q4 Results: Benchmarking Fortrea (NASDAQ:FTRE)
Let’s dig into the relative performance of Fortrea (NASDAQ:FTRE) and its peers as we unravel the now-completed Q4 drug development inputs & services earnings season. 
Via StockStory
A Look Back at Drug Development Inputs & Services Stocks’ Q4 Earnings: Repligen (NASDAQ:RGEN) Vs The Rest Of The Pack
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including Repligen (NASDAQ:RGEN) and... 
Via StockStory
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4
Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Charles River Laboratories (NYSE:CRL) and its peers. 
Via StockStory
2 Reasons to Watch MEDP and 1 to Stay Cautious
Medpace has been treading water for the past six months, recording a small loss of 4.4% while holding steady at $334.43. The stock also fell short of the S&P 500’s 7.6% gain during that period. 
Via StockStory
Topics Stocks
Why Medpace (MEDP) Shares Are Trading Lower Today
Shares of clinical research company Medpace Holdings (NASDAQ:MEDP) fell 8.7% in the pre-market session after the company reported weak fourth-quarter results: Medpace's full-year revenue, EPS, and... 
Via StockStory
Harmonic Issues Weak Guidance, Joins Fluence Energy, Amkor Technology And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
The regular session of the US market on Monday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Medpace Stock Falls On Q4 Earnings: The Details
Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report. 
Via Benzinga
Medpace (NASDAQ:MEDP) Posts Q4 Sales In Line With Estimates But Stock Drops
Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 7.7% year on year to $536.6 million. On the other hand, the company’s... 
Via StockStory
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2024 Results
From Medpace Holdings, Inc.
Via Business Wire
Earnings Scheduled For February 10, 2025
 
Via Benzinga
Medpace (MEDP) To Report Earnings Tomorrow: Here Is What To Expect
Clinical research company Medpace Holdings (NASDAQ:MEDP) will be announcing earnings results tomorrow after market hours. Here’s what to expect. 
Via StockStory
Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2024 Financial Results on February 10, 2025
From Medpace Holdings, Inc.
Via Business Wire
Medpace Holdings, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.